Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 599-608
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Table 3 Adverse events associated with coronavirus disease 2019 vaccination in published studies
Ref.
Sample size (n)
Cancer type
Systemic therapy
Vaccines administered
Patients with Grade 3 or worse AE, %
Immune-related AEs
Comment
Oosting et al[23]544Solid TumorsChemotherapy; Immunotherapy; ChemoimmunotherapymRNA-1273 (Moderna)10/544 (1.8%)4% in both immunotherapy and chemoimmunotherapy groupTotal 4 serious AEs were potentially related to the vaccination
Cavann et al[24]257Solid TumorsChemotherapy; Immunotherapy; Chemoimmunotherapy; Chemotherapy plus biological therapy; Biologic therapyPfizerModerna0/257 (0%)NAApproximately 1/3rd of patients reported mild local reactions (pain, erythema) at the injection site
Waissengrin et al[25]134Solid TumorsImmune checkpoint inhibitor; ChemoimmunotherapyBNT162b2 mRNA vaccine (Pfizer)0/134 (0%)Nonattributable to the vaccinationFatigue (34%), headache (16%), muscle pain (34%)
Di Noia et al[26]816Solid TumorsChemotherapy; Immunotherapy; Chemoimmunotherapy; Targeted therapyPfizer3.3% after the 1st dose, 1.4% after the second doseNAAE occurred in 359 (44%) and 301 (38.3%) patients after the first and second dose, respectively
Shmueli et al[27]129Solid TumorsChemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; RadiotherapyPfizer0/129 (0%)NAAE was reported by 39% of patients after the first dose and 58% of patients after the second dose- all mild to moderate in severity
Tamura et al[29]120Solid TumorChemotherapy; Immunotherapy; Targeted Therapy; ChemoimmunotherapyPfizer Moderna0/120 (0%); CTCAE was not used NAStudy limited to patients receiving treatment for lung cancer only. No serious AEs or treatment delay was observed
Kian et al[28]210Solid & Non-Solid TumorsChemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; Radiotherapy; Radio-hormonal; Chemo-biologicalPfizer0.004% after 1st dose, 1.9% after the second dose NAAE occurred in 65 (31%) and 65 (31%) patients after the first and second dose, respectively. Injection site pain was the most common AE after both doses